Wegovy is FDA-approved for long-term use, with no built-in end date. The medication is classified as a chronic weight management treatment, meaning it’s designed to be taken indefinitely, much like medications for high blood pressure or cholesterol. Most people who stop taking it regain a significant portion of the weight they lost.
Why Wegovy Is Considered a Long-Term Medication
The FDA approved Wegovy specifically for long-term weight reduction and maintenance. Its label reads “to reduce excess body weight and maintain weight reduction long term,” placing it in the same category as other medications you take continuously to manage an ongoing condition. Obesity is increasingly treated as a chronic disease rather than a temporary problem with a temporary fix, and Wegovy’s approval reflects that shift.
Clinical trials have tested the drug over periods ranging from 68 weeks to 104 weeks (two full years). In the longest trial, patients on the maintenance dose lost an average of 15.2% of their body weight at the two-year mark, compared to just 2.6% in the placebo group. That gap held steady over time, suggesting the drug continues working as long as you keep taking it.
What Happens When You Stop
This is the part most people searching this question really want to know. The short answer: weight comes back, and it comes back faster than most people expect.
A 2025 meta-analysis published in The Lancet tracked what happens after people discontinue GLP-1 medications like Wegovy. Within one year of stopping, people regained about 60% of the weight they had lost during treatment. The researchers estimated that regain eventually plateaus at around 75% of the lost weight. In practical terms, if you lost 40 pounds on Wegovy, you could expect to regain roughly 24 pounds within a year of stopping, and potentially 30 pounds over the longer term.
A separate systematic review published in The BMJ found that people regain weight at an average rate of about 0.9 pounds per month after stopping weight management medications. At that pace, the projected return to baseline weight is roughly 1.7 years after stopping. The regain isn’t because of willpower failure. Wegovy works by mimicking a hormone that reduces appetite and slows digestion. When the drug leaves your system, those appetite signals return to their previous levels, and your body’s drive to restore its former weight reasserts itself.
The Dose Escalation Timeline
Before you reach the maintenance dose, you’ll spend about 16 weeks gradually increasing your dose. This slow ramp-up exists to reduce nausea and other digestive side effects. The schedule looks like this:
- Weeks 1 through 4: 0.25 mg once weekly
- Weeks 5 through 8: 0.5 mg once weekly
- Weeks 9 through 12: 1 mg once weekly
- Weeks 13 through 16: 1.7 mg once weekly
- Week 17 onward: 1.7 mg or 2.4 mg once weekly (maintenance)
If you experience significant nausea or other side effects at any step, the escalation can be paused for an additional four weeks before moving up. The recommended maintenance dose for adults is 2.4 mg, though 1.7 mg is an alternative if the higher dose isn’t tolerated. Once you reach your maintenance dose at around week 17, that’s the dose you stay on going forward.
How Long It Takes to See Results
Weight loss begins during the escalation phase, but the most significant results build over months. In the 72-week STEP UP trial, patients on the highest dose achieved roughly 19% mean weight loss, translating to about 47 pounds on average. That didn’t happen in the first few months. Weight loss with Wegovy tends to be gradual and cumulative, with most of the effect playing out over the first year to year and a half. The two-year trial data shows that weight loss can continue, though at a slower pace, well into the second year of treatment.
Beyond Weight Loss: Cardiovascular Benefits
For some patients, the reason to stay on Wegovy extends beyond the number on the scale. The SELECT trial found that semaglutide at the 2.4 mg dose reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with existing heart disease and overweight or obesity. This finding led the FDA to expand Wegovy’s approved uses to include cardiovascular risk reduction, giving some patients a medical reason to continue the medication even if weight loss has plateaued.
Insurance and Renewal Requirements
If you’re on Wegovy through insurance, staying on the medication typically means meeting renewal criteria every 12 months. Requirements vary by insurer, but a common example from a major carrier requires that you maintain a BMI of 27 or above, continue following a reduced-calorie diet with regular physical activity, and don’t have a diabetes diagnosis. Authorizations are generally issued in 12-month blocks, so you’ll go through a reapproval process annually.
Some insurers have added coverage specifically for cardiovascular risk reduction or liver-related conditions, each with their own renewal criteria. If your coverage is denied at renewal, your prescriber’s office can often submit additional documentation to support continued authorization.
The Cost of Stopping and Restarting
Some people consider cycling on and off Wegovy to manage costs or side effects. The weight regain data suggests this approach has real downsides. Because roughly 60% of lost weight returns within the first year off the drug, stopping for even several months can erase a large portion of your progress. If you restart, you’ll need to go through the full 16-week dose escalation again, adding another four months before you’re back at your maintenance dose. The biological reality is that the medication works while you’re on it and largely stops working when you’re not.